Kleiner Perkins Raised $3.5 Billion in 2026 — Its Biggest Fund Ever, Aimed Squarely at AI

$3.5 billion is what Kleiner Perkins raised in March 2026 across two new funds — a $1 billion early-stage vehicle called KP22 and a $2.5 billion growth fund — up from roughly $2 billion in its last fund cycle two years earlier.

For most of the 2010s, Kleiner Perkins was the cautionary tale limited partners told each other: the firm that helped fund Google, Amazon, and Netscape, then sat out Facebook and much of the mobile wave that followed. This year it did the opposite of retreat. On March 24, 2026, Kleiner Perkins announced $3.5 billion in fresh capital split between an early-stage fund and a growth vehicle, both pointed almost entirely at artificial intelligence. The two funds are large enough on their own to rank among 2026's biggest venture closes, and they land at a moment when nearly every legacy Silicon Valley firm is running the same playbook — raise bigger, concentrate harder on AI, and use fresh capital to answer years of questions about whether the old brand names still deserve top billing. Here's what the two funds actually are, how the raise stacks up against the firm's own 54-year history, and why a single large check doesn't yet settle the question of whether the comeback is real.

Kleiner Perkins' New Fund in 2026: What KP22 Actually Is

Kleiner Perkins' new fund in 2026 is really two funds raised together: KP22, a $1 billion vehicle for early-stage bets, and KP Select IV, a $2.5 billion growth fund for follow-on checks into the firm's winners. Combined, that's $3.5 billion in fresh capital, with the firm's own announcement naming AI as the dominant theme across both vehicles.

According to TechCrunch's March 24, 2026 report and Bloomberg's same-day coverage, the $1 billion KP22 fund backs seed and Series A companies, while the $2.5 billion Select IV fund exists to defend Kleiner Perkins' ownership in later rounds of its most promising early bets — the same "don't get diluted out of your own winners" logic driving growth-fund launches across the industry this year. The firm's own post announcing the raise, "Our New Funds: KP22 and KP Select IV / Flex," frames the growth vehicle as a "Flex" structure built to move capital toward whichever portfolio companies are scaling fastest, rather than a fixed check-size ladder.

Trade coverage of the close, including reporting from Crunchbase News, put Kleiner Perkins' total assets under management at roughly $21 billion once the new capital closed — a figure that reflects five decades of fund vintages still being invested or held for eventual distribution, not cash sitting idle in one account. The firm is based in Menlo Park, California, the same address it has operated from since John Doerr joined as a partner in 1980, eight years after Eugene Kleiner and Tom Perkins founded it.

54 Years of Fund Raises: How $3.5B Compares to Kleiner Perkins' Own History

Kleiner Perkins has raised a new flagship fund roughly every two to four years since the early 2010s, and the size of each cycle has climbed steadily — but the jump from 2024 to 2026 is the sharpest in over a decade. KP21 and its companion growth fund, Select III, closed at a combined figure just over $2 billion in June 2024; two years later, KP22 and Select IV brought in $3.5 billion, a roughly 73% increase in one cycle.

The early-stage flagship itself has grown more slowly and steadily: $525 million for KP15 in May 2012, $600 million for KP18 in January 2019, then $700 million for KP19 in March 2020, a fund TechCrunch's report at the time called the firm's biggest to that point. The real acceleration is in the growth vehicles layered on top: Select II launched at $1 billion alongside KP20's January 2022 announcement, then Select III grew to $1.2 billion in 2024, and now Select IV more than doubles that again to $2.5 billion. In dollar terms, the growth fund has gone from nonexistent to 2.5 times the size of the original flagship vehicle in four years.

Sources: Kleiner Perkins fund announcements, TechCrunch (2012, 2020, 2022, 2026), and Bloomberg (2026) reporting on each close. KP21/Select III combined figure per Crunchbase News' contemporaneous "over $2 billion" report.

The AI Bet, Including a Healthcare-Specific Push

Kleiner Perkins' current AI portfolio already includes Anthropic, Waymo, Together AI, legal-AI company Harvey, and medical-search startup OpenEvidence, alongside historical wins like Google and Amazon that originally built the firm's brand. Partner Ilya Fushman, who leads much of the early-stage AI investing, also sits on the boards of Rippling, Motive, Stord, Profound, NewLimit, and Infinitus — a mix that spans infrastructure, vertical AI, and biotech, and a reminder that KP22 checks are not limited to companies with "AI" in their pitch deck's first line.

Crunchbase News' reporting on the March 2026 close named software, healthcare, and transportation as the three sectors Kleiner Perkins singled out for the new capital, a broader mandate than a pure foundation-model play would suggest — the firm is betting on AI applied across existing industries at least as much as on the underlying models themselves. The clearest sign of where the new capital is headed came four months after the raise, when Kleiner Perkins and Chairman John Doerr's personal vehicle, Doerr Capital, teamed up with UCSF Health to launch Converge, a healthcare-AI accelerator, according to Fortune's July 15, 2026 report. The program pairs selected startups with UCSF clinicians and operators to validate AI tools inside real care-delivery settings, with Doerr and partner Mamoon Hamid personally involved in mentoring the cohort — an unusually hands-on structure for a firm this size, and one that signals healthcare is a named priority for KP22 and Select IV capital, not just a category mentioned in passing.

Hamid, who co-founded Social Capital's venture practice in 2011 and joined Kleiner Perkins as a general partner in August 2017, built his track record on enterprise software bets including Slack, Box, and Intercom before the current AI cycle began. He has emerged alongside Doerr and Fushman as the third public face of the AI push, with the UCSF Health partnership as his most visible 2026 project. That three-person leadership structure — a chairman who has been at the firm since 1980, a partner who arrived in 2017 with an enterprise-software pedigree, and a partner whose board seats span fintech, legal, and logistics — is part of the pitch to limited partners: continuity at the top, paired with investors who each built reputations before AI became the default thesis at every firm.

How $3.5B Stacks Up Against 2026's Other Mega-Funds

Kleiner Perkins' $3.5 billion is a large raise by its own standards but a middle-of-the-pack number next to 2026's biggest venture closes. The common thread across nearly every one of these firms is the growth-fund add-on: none is simply raising a bigger early-stage vehicle alone — each is layering a sizable late-stage pool on top, all within the same twelve-month stretch. Andreessen Horowitz raised roughly $15 billion this year, according to its own fund disclosures covered in our breakdown of a16z's Fund VII, and Lightspeed Venture Partners closed $9 billion of its own. Bessemer Venture Partners raised slightly more than Kleiner Perkins, closing a $3.85 billion fund on June 22, 2026 that PitchBook reported was the ninth-largest individual U.S. VC fund ever raised. By contrast, Benchmark's first-ever growth fund brought in $2 billion the same June.

What the Headline Misses

A $3.5 billion raise reads as a clean comeback story, but Kleiner Perkins has been here before without it sticking. Fortune's longform account, "How the Kleiner Perkins Empire Fell," documents how the firm sat out Facebook and much of the 2000s Web 2.0 wave, then spent years failing to land the decade's hottest early-stage deals while a costly cleantech detour ate up capital and attention. One longtime limited partner told Fortune around 2015 that the brand had "been dilutive to our returns for a long period" — a blunt assessment from someone who kept re-upping anyway, on the strength of the name alone.

Raising money is also not the same as deploying it well. KP19 was reported as the firm's biggest fund to date when it closed in March 2020, and KP21 held that title again in 2024 — a pattern of each new fund being framed as the turnaround vehicle, without independent public data yet showing whether the intervening vintages actually delivered top-quartile returns. A fund this large, this concentrated in one sector, also means Kleiner Perkins is now more exposed than most peers to a single scenario: if AI valuations correct sharply before these vintages mature, a firm still rebuilding its reputation has less room to absorb the miss than a multi-strategy platform like Andreessen Horowitz.

One likely read on this: nearly every top-tier firm named in this piece — a16z, Lightspeed, Bessemer, Kleiner Perkins, and Benchmark — closed a mega-fund within months of each other in 2026, almost entirely pointed at the same narrow set of AI companies. That is not proof of a bubble by itself, but it does mean limited partners are making a coordinated, concentrated bet across nearly their whole venture book at once, and Kleiner Perkins' $3.5 billion is one slice of a much larger industry wager rather than a contrarian call.

The Bottom Line for Founders and LPs

For AI founders, Kleiner Perkins in 2026 is a firm with real dry powder and a specific playbook: get funded by KP22 at seed or Series A, and there's now a dedicated $2.5 billion Select IV pool built to keep writing checks into later rounds instead of watching the position get crowded out. The UCSF Health partnership also makes Kleiner Perkins a genuinely differentiated option for healthcare-AI founders specifically, not just another generalist AI check, while the software and transportation focus named alongside healthcare suggests the firm is still writing checks well outside pure foundation-model plays.

For limited partners, the honest read is that $3.5 billion is a bet on this specific team — Doerr, Hamid, and Fushman — proving out an AI thesis in a market where nearly every top-tier firm is making the same wager with comparable or larger checkbooks. The fund size alone doesn't resolve the decade-old question about Kleiner Perkins' pace of returns; that will only get answered when KP22 and Select IV's portfolio companies start marking up, several years from now.

What's verifiable today is narrower than the headline: Kleiner Perkins closed $3.5 billion on March 24, 2026, brought total firm assets to roughly $21 billion, and has since put a specific, hands-on healthcare-AI program in front of the market. Whether that adds up to the firm reclaiming the standing it held when it backed Google and Amazon is a multi-year question the fund size alone cannot answer.